Published in Cancer Cell Int on June 10, 2009
Blechnum orientale Linn - a fern with potential as antioxidant, anticancer and antibacterial agent. BMC Complement Altern Med (2010) 1.16
Anti-tumor activity of Eurycoma longifolia root extracts against K-562 cell line: in vitro and in vivo study. PLoS One (2014) 0.79
The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells. PLoS One (2015) 0.77
Evaluation of Acute 13-Week Subchronic Toxicity and Genotoxicity of the Powdered Root of Tongkat Ali (Eurycoma longifolia Jack). Evid Based Complement Alternat Med (2013) 0.76
Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections. Front Microbiol (2015) 0.75
Isolation and Characterisation of a Proanthocyanidin With Antioxidative, Antibacterial and Anti-Cancer Properties from Fern Blechnum orientale. Pharmacogn Mag (2017) 0.75
Review Ergogenic Effect of Long Jack, Eurycoma Longifolia. Pharmacogn Rev (2017) 0.75
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell (1996) 16.73
The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (1997) 15.25
Natural products as sources of new drugs over the period 1981-2002. J Nat Prod (2003) 8.03
Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A (1998) 6.69
Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem (1999) 6.59
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev (2005) 4.72
Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature (1998) 4.02
Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med (2005) 3.66
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97
Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene (2006) 2.49
p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem (2000) 2.14
Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods (1997) 1.89
Plant-derived anticancer agents. Biochem Pharmacol (1997) 1.87
Apoptosis and the dilemma of cancer chemotherapy. Blood (1997) 1.71
Cytotoxic and antimalarial constituents of the roots of Eurycoma longifolia. J Nat Prod (1992) 1.62
Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res (1997) 1.60
Scientific evaluation of traditional Chinese medicine under DSHEA: a conundrum. Dietary Supplement Health and Education Act. J Altern Complement Med (1999) 1.43
Mammalian G1 and G2 phase checkpoints. Cancer Surv (1997) 1.41
Cytotoxicity of some medicinal plant extracts used in Tanzanian traditional medicine. J Ethnopharmacol (2000) 1.28
ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett (2004) 1.20
Cytotoxic and antimalarial constituents from the roots of Eurycoma longifolia. Bioorg Med Chem (2004) 1.17
Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species. Eur J Pharmacol (2007) 1.13
Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci (2004) 1.08
Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int (2005) 1.06
Anti-proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett (2005) 1.06
Induction of apoptosis in HepG2 cells by solanine and Bcl-2 protein. J Ethnopharmacol (2007) 1.01
The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter (2004) 1.00
In vitro anti-tumor promoting and anti-parasitic activities of the quassinoids from Eurycoma longifolia, a medicinal plant in Southeast Asia. J Ethnopharmacol (2002) 0.99
Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem (2003) 0.97
p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol (2005) 0.95
Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res (1990) 0.94
Aqueous extract of herba Scutellaria barbatae, a chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines. Gynecol Oncol (2003) 0.92
Apoptosis in tumorigenesis and cancer therapy. Front Biosci (1997) 0.91
Potential roles for p53 in nucleotide excision repair. Carcinogenesis (1999) 0.90
Genetic diversity of Eurycoma longifolia inferred from single nucleotide polymorphisms. Plant Physiol (2003) 0.88
Induction of apoptosis by Eurycoma longifolia jack extracts. Anticancer Res (2005) 0.85
Taiwanin A induced cell cycle arrest and p53-dependent apoptosis in human hepatocellular carcinoma HepG2 cells. Life Sci (2006) 0.85
Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res (1994) 0.85
Detection of serum p53 protein in patients with different gastrointestinal cancers. Cancer Detect Prev (2003) 0.83
High performance liquid chromatography analysis of canthinone alkaloids from Eurycoma longifolia. Planta Med (2002) 0.82
Constituents of Eurycoma longifolia Jack. J Org Chem (1970) 0.78
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54
Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27
Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24
Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91
IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85
Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell (2003) 1.84
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
Antioxidant activities, total phenolics and flavonoids content in two varieties of Malaysia young ginger (Zingiber officinale Roscoe). Molecules (2010) 1.68
Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66
Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res (2003) 1.63
Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem (2002) 1.61
Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol (2007) 1.61
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs (2002) 1.52
Retracted FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol (2005) 1.51
Carica papaya Leaves Juice Significantly Accelerates the Rate of Increase in Platelet Count among Patients with Dengue Fever and Dengue Haemorrhagic Fever. Evid Based Complement Alternat Med (2013) 1.51
Effects of soy on metabolic biomarkers of cardiovascular disease in elderly women with metabolic syndrome. Arch Iran Med (2012) 1.50
Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav (2003) 1.48
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther (2011) 1.45
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res (2004) 1.41
Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem (2005) 1.41
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol (2006) 1.38
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem (2002) 1.37
Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem (2004) 1.37
Antioxidant activity of methanol extracts obtained from Plantago species. J Agric Food Chem (2005) 1.32
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther (2006) 1.32
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med (2003) 1.30
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol (2009) 1.29
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther (2007) 1.28
Elevated carbon dioxide increases contents of flavonoids and phenolic compounds, and antioxidant activities in Malaysian young ginger (Zingiber officinale Roscoe.) varieties. Molecules (2010) 1.27
In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer. J Ethnopharmacol (2004) 1.27
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics (2002) 1.26
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.26
Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res (2003) 1.26
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res (2003) 1.26
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.25
SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer (2008) 1.23
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res (2006) 1.23
Assessment of antiproliferative and antiplasmodial activities of five selected Apocynaceae species. BMC Complement Altern Med (2011) 1.22
RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther (2013) 1.21
Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res (2013) 1.20
Screening of antiplasmodial properties among some traditionally used Iranian plants. J Ethnopharmacol (2008) 1.20
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.20
Antiplasmodial studies of Eurycoma longifolia Jack using the lactate dehydrogenase assay of Plasmodium falciparum. J Ethnopharmacol (2004) 1.19
Cardiovascular effects of ginger aqueous extract and its phenolic constituents are mediated through multiple pathways. Vascul Pharmacol (2005) 1.18
A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res (2003) 1.17
IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell (2006) 1.17
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 1.16
Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J Biol Chem (2002) 1.16
Antibacterial, antioxidant and fibroblast growth stimulation of aqueous extracts of Ficus asperifolia Miq. and Gossypium arboreum L., wound-healing plants of Ghana. J Ethnopharmacol (2008) 1.15
Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.14
Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther (2011) 1.13
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 1.13
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 1.13
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol (2005) 1.12
Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytother Res (2007) 1.11
The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Mol Cell Biol (2009) 1.11
Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb Perspect Med (2014) 1.10
Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets (2004) 1.10
Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo. Mol Cell Biol (2007) 1.09
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 1.08
In vitro inhibitory activities of plants used in Lebanon traditional medicine against angiotensin converting enzyme (ACE) and digestive enzymes related to diabetes. J Ethnopharmacol (2008) 1.07
Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs (2007) 1.06
Identification and concentration of some flavonoid components in Malaysian young ginger (Zingiber officinale Roscoe) varieties by a high performance liquid chromatography method. Molecules (2010) 1.06
Effects of acute gamma irradiation on physiological traits and flavonoid accumulation of Centella asiatica. Molecules (2011) 1.06
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.05
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05
O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther (2002) 1.04
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol (2006) 1.03
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med (2005) 1.03
miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci Signal (2013) 1.02
Wilms tumor suppressor 1 (WT1) and early growth response 1 (EGR1) are regulators of STIM1 expression. J Biol Chem (2010) 1.02
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol (2004) 1.02
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res (2002) 1.01
Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med (2004) 1.00
Wound healing activity of acylated iridoid glycosides from Scrophularia nodosa. Phytother Res (2002) 1.00
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.00
Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One (2012) 0.99
Synthesis of phenolics and flavonoids in ginger (Zingiber officinale Roscoe) and their effects on photosynthesis rate. Int J Mol Sci (2010) 0.99
Anti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule. PLoS One (2012) 0.99
mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. J Biol Chem (2007) 0.99
Antiproliferative property and apoptotic effect of xanthorrhizol on MDA-MB-231 breast cancer cells. Anticancer Res (2009) 0.99
Virtual docking approaches to protein kinase B inhibition. J Med Chem (2005) 0.98